164 related articles for article (PubMed ID: 19537521)
1. Relevance of metabolic activation pathways: the example of clopidogrel and prasugrel.
Petersen KU
Arzneimittelforschung; 2009; 59(5):213-27. PubMed ID: 19537521
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
Chen CH; Yang JC; Uang YS; Lin CJ
Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
[TBL] [Abstract][Full Text] [Related]
3. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Li YG; Ernest CS; Payne CD; Salazar DE; Winters KJ
Curr Med Res Opin; 2008 Aug; 24(8):2251-7. PubMed ID: 18786302
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, drug metabolism, and safety of prasugrel and clopidogrel.
Achar S
Postgrad Med; 2011 Jan; 123(1):73-9. PubMed ID: 21293086
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic basis of the antiplatelet action of prasugrel.
Schrör K; Siller-Matula JM; Huber K
Fundam Clin Pharmacol; 2012 Feb; 26(1):39-46. PubMed ID: 21895761
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
Lettino M
Eur J Intern Med; 2010 Dec; 21(6):484-9. PubMed ID: 21111931
[TBL] [Abstract][Full Text] [Related]
7. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs.
Hagihara K; Kazui M; Ikenaga H; Nanba T; Fusegawa K; Takahashi M; Kurihara A; Okazaki O; Farid NA; Ikeda T
Xenobiotica; 2009 Mar; 39(3):218-26. PubMed ID: 19280520
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
9. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.
Brandt JT; Close SL; Iturria SJ; Payne CD; Farid NA; Ernest CS; Lachno DR; Salazar D; Winters KJ
J Thromb Haemost; 2007 Dec; 5(12):2429-36. PubMed ID: 17900275
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.
Ancrenaz V; Daali Y; Fontana P; Besson M; Samer C; Dayer P; Desmeules J
Curr Drug Metab; 2010 Oct; 11(8):667-77. PubMed ID: 20942779
[TBL] [Abstract][Full Text] [Related]
11. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
Small DS; Farid NA; Payne CD; Weerakkody GJ; Li YG; Brandt JT; Salazar DE; Winters KJ
J Clin Pharmacol; 2008 Apr; 48(4):475-84. PubMed ID: 18303127
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor and clopidogrel interaction: fact or fiction?
Laine L; Hennekens C
Am J Gastroenterol; 2010 Jan; 105(1):34-41. PubMed ID: 19904241
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
[TBL] [Abstract][Full Text] [Related]
15. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
16. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
[TBL] [Abstract][Full Text] [Related]
17. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy.
Hochholzer W; Trenk D; Mega JL; Morath T; Stratz C; Valina CM; O'Donoghue ML; Bernlochner I; Contant CF; Guo J; Sabatine MS; Schömig A; Neumann FJ; Kastrati A; Wiviott SD; Sibbing D
Am Heart J; 2011 Sep; 162(3):518-26.e5. PubMed ID: 21884870
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Jakubowski JA; Winters KJ; Naganuma H; Wallentin L
Cardiovasc Drug Rev; 2007; 25(4):357-74. PubMed ID: 18078435
[TBL] [Abstract][Full Text] [Related]
19. Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel.
Ma TK; Lam YY; Tan VP; Kiernan TJ; Yan BP
Pharmacol Ther; 2010 Feb; 125(2):249-59. PubMed ID: 19919843
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
